BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

Umberto Malapelle, Giulio Rossi, Pasquale Pisapia, Massimo Barberis, Fiamma Buttitta, Francesca Castiglione, Fabiana Letizia Cecere, Antonio Maria Grimaldi, Antonino Iaccarino, Antonio Marchetti, Daniela Massi, Daniela Medicina, Fabio Mele, Roberta Minari, Elisabetta Orlando, Fabio Pagni, Giuseppe Palmieri, Luisella Righi, Alessandro Russo, Stefania TommasiWilliam Vermi, Giancarlo Troncone

Research output: Contribution to journalReview articlepeer-review


In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided.

Original languageEnglish
Article number103118
JournalCritical Reviews in Oncology/Hematology
Publication statusPublished - Dec 2020


  • BRAF
  • Lung cancer
  • Melanoma
  • Precision medicine
  • Predictive molecular pathology

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients'. Together they form a unique fingerprint.

Cite this